Fusion proteins

US9243301B2 · kind B2 · utility

Assignees

• Allergan, Inc. · US
• IPSEN BIOINNOVATION LIMITED · GB

Inventors

• Keith Foster · Salisbury, GB
• John Chaddock · Shrewsbury, GB
• Philip Marks · Shrewsbury, GB
• Patrick Stancombe · Salisbury, GB
• Kei Roger Aoki · Coto De Caza, US
• Joseph Francis · Irvine, US
• Lance E. Steward · Irvine, US

Key dates

• Filing date: Mar 13, 2012
• Grant date: Jan 26, 2016
• Expiry date: Sep 18, 2033

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2319/50
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

A single chain, polypeptide fusion protein, comprising: a non-cytotoxic protease, or a fragment thereof, which protease or protease fragment can cleave a protein of the exocytic fusion apparatus of a nociceptive sensory afferent; a Targeting Moiety that can bind to a Binding Site on the nociceptive sensory afferent, which Binding Site can undergo endocytosis to be incorporated into an endosome within the nociceptive sensory afferent; a protease cleavage site at which site the fusion protein is cleavable by a protease, which is located between the non-cytotoxic protease and the Targeting Moiety; and a translocation domain that can translocate the protease or protease fragment from within an endosome, across the endosomal membrane and into the cytosol of the nociceptive sensory afferent; wherein the Targeting Moiety is BAM, β-endorphin, bradykinin, substance P, dynorphin and/or nociceptin. Nucleic acid sequences encoding the fusion proteins, methods of preparing same and uses thereof are also described.